Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.

Conditions

Locally Advanced Cholangiocarcinoma Intrahepatic Cholangiocarcinoma Solid Tumor Metastatic Cholangiocarcinoma

Interventions / Drugs

Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment40 participants

Primary Completion—

Lead SponsorTyra Biosciences, Inc

Data Retrieved2026-04-11 04:30:22.593333+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.